OZURDEX (dexamethasone) by AbbVie is corticosteroid hormone receptor agonists [moa]. First approved in 2009.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
OZURDEX is a dexamethasone intravitreal implant approved in 2009 for ocular inflammation and macular edema. It is a small-molecule corticosteroid that works via glucocorticoid receptor agonism to suppress inflammatory pathways in the eye. The implant provides sustained local drug delivery over several months.
Product approaching loss of exclusivity with modest Medicare spending (~$2M annually), suggesting contracting commercial footprint and potential team rightsizing.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Worked on OZURDEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moOZURDEX offers limited near-term career expansion due to its LOE-approaching lifecycle and modest commercial scale ($2M Part D spending, 1,047 claims in 2023). Roles tied to this product are primarily in defensive commercial and access management rather than growth-phase functions.